Skip to main content
OpenTrials
Completed

NCT Number: NCT02019927

Electric Stimulation of the Eye to Improve Vision After Trauma

Transcorneal Electrical Stimulation (TES) using the "OkuStim®" device delivers electrical impulses to damaged and/or diseased photoreceptor cells. This electric stimulation of the retina may help to preserve visual acuity and/or the visual field.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The finely detailed, precise anatomy of the retina and optic nerve capture light impulses from the environment through a biochemical process and then transmit these images to the brain via electrical impulses conducted from the inner retina to the optic nerve and ultimately to the occipital cortex.

In the human eye, three types of specialized ganglion cells transmit electrical impulses to the brain. Among these three cell populations are rod and cone cells, which participate in the photo-transduction step of light perception, along with other light sensitive ganglion cells. It is a system whereby the photosensitive pigment rhodopsin (or one of its analogs) rearranges in response to light, and this change in chemical structure fires electrical impulses to the brain which in turn interprets the incoming impulses as a visual image.

Transcorneal Electrical Stimulation (TES) using the "OkuStim®" device delivers electrical impulses to damaged and/or diseased photoreceptor cells. This electric stimulation of the retina may help to preserve VA and/or the visual field.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • You are 18 years or older.
  • You have sustained trauma (more than 3 months before this study) OR been diagnosed with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (more than 6 months before this study) OR been diagnosed with Multiple Sclerosis (MS) and suffered visual loss (more than 3 months before this study).
  • You are willing and able to give written informed consent.
  • You are able to commit to enrolling in the study during the full time period of up to 6 months.

Exclusion criteria

  • You have any other significant ophthalmologic disease or condition (such as glaucoma, retinal degeneration, proliferative diabetic retinopathy, +/- six diopters of myopia, retinal detachment, exudative age-related macular degeneration).
  • You have amblyopia (lazy eye) in affected eye, previously diagnosed.
  • You are participating in any other interventional clinical trial.
  • If you are pregnant OR a woman with childbearing potential who is unwilling to use medically acceptable means of birth control for study duration OR woman unwilling to perform a pregnancy test at study entry/screening.
  • You are unable to give signed consent due to memory, medical, communication, language, or mental health problems.
  • You are less than 18 years old.
  • You are unable or unwilling to complete the evaluation or questionnaire.
  • Visual acuity better than 20/40
  • Inability to detect phosphenes during threshold detection
  • You are on seizure medications, or have a history of epilepsy.

Treatment and study plan

Transcorneal Electrical Stimulation

Device

The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.

Other names: TES, OkuVision

SHAM

Device

Sham

Primary outcomes

  1. Evaluation of the Effectiveness and Safety of Transcorneal Electrical Stimulation to Improve Visual Acuity

    Time frame: Change from Baseline (week 1) to 1-week post initial treatment (week 8)

    The primary outcomes are change in high-contrast LogMar VA from baseline (week 1) to initial post treatment (week 8). Participants read letters from a chart and receive 1 point for each letter correctly identified. Scores are converted to logMAR scale and analyzed for changes in visual acuity. Improvement in visual acuity is defined as a decrease in logMAR of 0.2 or more.

Secondary outcomes

  1. Intra-Ocular Pressure (IOP)

    Time frame: Change from Baseline (week 1) to 1-week post initial treatment (week 8)

    Measured by Applanation (Galdmann) Tonometry method

  2. Visual Field Mean Deviation

    Time frame: Change from Baseline (week 1) to 1 - week post initial treatment (week 8)

    The Humphrey 24-2 Swedish Interactive Threshold Algorithm Standard perimeter was used to test visual field. Reported values are a change from baseline to 1-week post initial treatment.

  3. Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Superior Quadrant

    Time frame: Change from Baseline (week 1) to 1 - week post initial treatment (week 8)

    Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline

  4. Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Nasal Quadrant

    Time frame: Change from Baseline (week 1) to 1 - week post initial treatment (week 8)

    Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline

  5. Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Inferior Quadrant

    Time frame: Change from Baseline (week 1) to 1 - week post initial treatment (week 8)

    Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline

  6. Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Temporal Quadrant

    Time frame: Change from Baseline (week 1) to 1 - week post initial treatment (week 8)

    Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline

  7. Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Center Quadrant

    Time frame: Change from Baseline (week 1) to 1 - week post initial treatment (week 8)

    Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline

  8. National Eye Institute's Visual Functioning Questionnaire - 25

    Time frame: Change from Baseline to 1 - week post initial treatment

    Test to measure Unweighted of scores within test ranging from 0-100 with higher scores meaning better outcome

  9. Symbol Digit Modality Testing

    Time frame: Change from Baseline to 1 - week post initial treatment

    Scores range from 0-110 with higher scores meaning better visual information processing speed

Sponsors and collaborators

Lead sponsor

Wills Eye

Other

Collaborators

  • United States Department of Defense

Registry information

Official study title

Evaluation of the Effectiveness and Safety of Transcorneal Electrical Stimulation to Improve Visual Function After Ocular Trauma

Acronym: TES

Important dates

Study start
2013
Primary completion
2017
Study completion
2017
First posted
Dec 24, 2013
Registry last updated
Jan 18, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.